Abstract
People with HIV (PWH) are at elevated risk for cardiovascular diseases (CVDs), including myocardial infarction, heart failure, and sudden cardiac death, among other CVD manifestations. Chronic immune dysregulation resulting in persistent inflammation is common among PWH, particularly those with sustained viremia and impaired CD4+ T cell recovery. This inflammatory milieu is a major contributor to CVDs among PWH, in concert with common comorbidities (such as dyslipidemia and smoking) and, to a lesser extent, off-target effects of antiretroviral therapy. In this review, we discuss the clinical and mechanistic evidence surrounding heightened CVD risks among PWH, implications for specific CVD manifestations, and practical guidance for management in the setting of evolving data.
Original language | English (US) |
---|---|
Article number | e00098-22 |
Journal | Clinical microbiology reviews |
Volume | 37 |
Issue number | 1 |
DOIs | |
State | Published - Mar 2024 |
Funding
The work for this review was funded in part by National Institutes of Health awards R01HL156792 and R01HL154862.
Keywords
- cardiovascular disease
- human immunodeficiency virus
- inflammation
ASJC Scopus subject areas
- General Medicine